Classification of HER2-negative breast cancers by

HER2 METABRIC TCGA copy number alteration genomics

Journal

Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808

Informations de publication

Date de publication:
2023
Historique:
received: 19 04 2023
accepted: 21 09 2023
medline: 3 11 2023
pubmed: 3 11 2023
entrez: 3 11 2023
Statut: epublish

Résumé

Recently, HER2-negative breast cancers have been reclassified by protein expression into 'HER2-low' and 'HER2-zero' subgroups, but the consideration of HER2-low breast cancer as a distinct biological subtype with differing prognoses remains controversial. By contrast, non-neutral Here, we investigated the molecular landscape of non-metastatic HER2-negative BCs in relation to Nearly two-fifths of the cohort harbored Classification of HER2-negative BCs according to

Sections du résumé

Background UNASSIGNED
Recently, HER2-negative breast cancers have been reclassified by protein expression into 'HER2-low' and 'HER2-zero' subgroups, but the consideration of HER2-low breast cancer as a distinct biological subtype with differing prognoses remains controversial. By contrast, non-neutral
Methods UNASSIGNED
Here, we investigated the molecular landscape of non-metastatic HER2-negative BCs in relation to
Results UNASSIGNED
Nearly two-fifths of the cohort harbored
Conclusion UNASSIGNED
Classification of HER2-negative BCs according to

Identifiants

pubmed: 37920257
doi: 10.1177/17588359231206259
pii: 10.1177_17588359231206259
pmc: PMC10619358
doi:

Types de publication

Journal Article

Langues

eng

Pagination

17588359231206259

Informations de copyright

© The Author(s), 2023.

Références

Eur J Cancer. 2019 Oct;120:65-74
pubmed: 31493723
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
JAMA Oncol. 2022 Apr 01;8(4):1-4
pubmed: 35113160
Genome Biol. 2014;15(12):550
pubmed: 25516281
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
NPJ Breast Cancer. 2021 Jan 4;7(1):1
pubmed: 33397968
Nat Commun. 2018 Sep 4;9(1):3476
pubmed: 30181556
JAMA Oncol. 2022 Aug 1;8(8):1177-1183
pubmed: 35737367
Breast Cancer. 2022 Mar;29(2):234-241
pubmed: 34622383
Breast Cancer Res. 2021 Dec 14;23(1):112
pubmed: 34906198
Bioinformatics. 2014 Apr 15;30(8):1056-1063
pubmed: 24389661
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
BMC Med. 2022 Mar 17;20(1):105
pubmed: 35296300
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32792358
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Lancet Oncol. 2021 Aug;22(8):1151-1161
pubmed: 34252375
Nat Med. 2023 Aug;29(8):2110-2120
pubmed: 37488289
Breast. 2021 Dec;60:62-69
pubmed: 34481367
Genome Biol. 2011;12(4):R41
pubmed: 21527027
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Breast Cancer Res. 2022 Mar 21;24(1):22
pubmed: 35307014
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Br J Cancer. 1999 Aug;80(12):1968-73
pubmed: 10471047
Eur J Cancer. 2021 Sep;155:1-12
pubmed: 34311211
Cancer Res. 2004 Sep 15;64(18):6453-60
pubmed: 15374954
J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45
pubmed: 9701363
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
Eur J Cancer. 2023 Jul;188:152-160
pubmed: 37247580
J Mol Diagn. 2017 Mar;19(2):244-254
pubmed: 28027945
Front Genet. 2018 Oct 01;9:421
pubmed: 30337938
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Breast Cancer Res. 2011;13(6):R129
pubmed: 22169037
Mod Pathol. 2009 Sep;22(9):1169-75
pubmed: 19448591
PLoS One. 2018 Nov 28;13(11):e0207776
pubmed: 30485330
Sci Transl Med. 2017 Mar 1;9(379):
pubmed: 28251903
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Elife. 2018 Sep 04;7:
pubmed: 30178746
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
JAMA Oncol. 2022 Apr 1;8(4):610-611
pubmed: 35113131
Clin Cancer Res. 2019 Dec 15;25(24):7413-7423
pubmed: 31515453
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153

Auteurs

Jui Wan Loh (JW)

Cancer Discovery Hub, National Cancer Centre Singapore, Singapore.

Abner Herbert Lim (AH)

Cancer Discovery Hub, National Cancer Centre Singapore, Singapore.

Jason Yongsheng Chan (JY)

Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Blvd, Singapore 168583.
Cancer Discovery Hub, National Cancer Centre Singapore, 30 Hospital Blvd, 168583.
Duke-NUS Medical School, 8 College Rd, Singapore 169857.

Yoon-Sim Yap (YS)

Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Blvd, Singapore 168583.
Duke-NUS Medical School, 8 College Rd, Singapore 169857.

Classifications MeSH